Stay updated on Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial
Sign up to get notified when there's something new on the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page.

Latest updates to the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has removed detailed descriptions of a clinical trial for myelodysplastic syndrome, including objectives, treatment outlines, and inclusion/exclusion criteria, while adding a new registry identifier and collaborators.SummaryDifference39%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 13, 2025. However, the deletion of the date March 25, 2025, does not significantly impact the core content.SummaryDifference0.4%
- Check37 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous date of February 13, 2025, and version 2.14.2.SummaryDifference0.3%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check80 days agoChange DetectedThe webpage has updated its date references, removing past dates from August 2024 and adding new dates in February 2025.SummaryDifference0.8%
Stay in the know with updates to Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page.